IDbyDNA Participates in NIH National COVID-19 Genomics Consortium
May 7, 2020
The CDC is leading the national SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance initiative (SPHERES) to coordinate SARS-CoV-2 sequencing across the U.S. Utah’s own IDbyDNA will be participating in the effort along with clinical and public health laboratories, academic institutions, and other private sector companies. The SPHERES consortium aims to generate information about the virus that will strengthen COVID-19 mitigation strategies.
In addition to IDbyDNA, corporate participants include Abbott Diagnostics, BioMérieux, Color, Ginkgo Bioworks, Illumina, In-Q-Tel, LabCorp, One Codex, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Quest Diagnostics, and Verily Life Sciences.
Recent News
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis